论文部分内容阅读
本文介绍了用COMFP五联方案联合治疗晚期、局部复发和转移性乳腺癌37例。均为女性,平均年龄46岁。全组26例有效(CR+PR),其有效率70.27％,Ⅱ期和Ⅳ期共11例,既往未作过任何治疗,有效率为81.81％。有效组中位缓解期7个月,中位生存期9.5个月,一年生存率76.92％(10/13例),二年生存率37.5％(3/8例),1例存活3年。无效组中位生存期6个月,一年生存率33.33％(2/6例),无一例生存2年者。本方案以给药3周间歇2周为一周期,两个周期为一疗程为宜。
This article describes the use of COMFP combined regimen for the treatment of 37 patients with advanced, locally recurrent and metastatic breast cancer. All are female, with an average age of 46 years old. In the whole group, 26 cases were effective (CR+PR), and the effective rate was 70.27%. There were 11 cases in phase II and IV. No treatment was performed in the past and the effective rate was 81.81%. The median remission period of the effective group was 7 months, and the median survival period was 9.5 months. The one-year survival rate was 76.92% (10/13 cases), the two-year survival rate was 37.5% (3/8 cases), and 1 case survived for 3 years. The median survival time of the invalid group was 6 months. The one-year survival rate was 33.33% (2/6 cases). No one survived 2 years. This protocol is based on a three-week dosing period of two weeks as a cycle, and two cycles are appropriate for one course of treatment.